U.S. Markets closed

Jazz Pharmaceuticals Public Limited Company (JAZZ)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
151.11-0.94 (-0.62%)
At close: 4:00PM EDT
People also watch
ALXNBMRNREGNMDVNICPT
  • Comapnies like jazz who are charging billions of dollars for drugs whose patents should have expired a long time ago and let generics hit the market have destroyed American families. We pay 30 thousand a year for health care so that these pharma companies can make hedge funds and other wall st crooks rich and ofcourse jazz executives rich while we suffer. Less time with our families less vacation etc. Our quality of life has been destroyed so they can have their mansions and good life.
  • I am very eager to see what jazz is up to in the near future to manipulate it's stock higher. They are always up to something some announcement that makes xyrem and themselves above the law. These market makers are a bunch of criminals and manipulate the stock on inside info
  • Thanks for the tip, I did some research and found more information about $JAZZ on http://thesubwaytrader.com/?s=JAZZ Day trading making money. The only rose without thorns is friendship.

    The Subway Trader: Trading Stocks and Making Money
    Stock alerts from the The Subway Trader. Stock trading, making money and always looking for the next big money maker.
    thesubwaytrader.com
  • AXSM (MC $85 M)(Cash $60 M) 5x BIG Phase 3 in various indications targeting large Markets with first interim results in Q3 2017 = 2000% POTENTIAL..UNKNOWN LOW FLOAT GEM !!!

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $85 million and $60 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $85 Million
    Cash: $60.6 Million(cash runway into the first quarter of 2019.)
    Price:$3.70

    Shares Out: 23 Million

    Anticipated Near-Term Clinical Milestones

    Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)

    Clinical Trial Readouts:

    -- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)

    -- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)

    -- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)

    New Presentation April
    http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjY0Mzk1fENoaWxkSUQ9MzcyMTk4fFR5cGU9MQ==&t=1

    HUGE Pipeline targeting Billion Dollar Markets:
    http://axsome.com/wp-content/uploads/2016/11/Axsome_Dec2016_Pipeline.png

    AXS-05 Treatment Resistant Depression in Phase 3 -(Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.)

    AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3 -(No approved medication = unmet medical need. 2M patients in the U.S.)

    AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status) -(No approved drug = high unmet need. 80,000 new cases per year in the U.S.)

    AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track) -(7M patients in the U.S.)

    AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 -(1.6M patients in the U.S.)

    Major Shareholders

    Herriott Tabuteau, MD 7 351 729 38,4%
    Fidelity Management & Research Co. 2 361 625 12,3%
    JPMorgan Asset Management (UK) Ltd. 1 432 456 7,48%
    Mark Coleman, MD 647 998 3,38%
    BlackRock Fund Advisors 426 837 2,23%
    Stifel Trust Co., NA 415 279 2,17%
    The Vanguard Group, Inc. 272 189 1,42%
    Lombard Odier Asset Management (USA) Corp. 250 000 1,31%
    JPMorgan Investment Management, Inc. 156 625 0,82%
    SSgA Funds Management, Inc. 134 688 0,70%

  • Jazz has been manipulating their stock fraudulently over the past 8 years in various ways. First and foremost is the overcharging by billions for xyrem. A drug they bought for 140 million dollars. A drug that was over the counter 40 years ago. Orphan medical was a criminal company. Jazz has a way of manipulating its stock by manipulating news on xyrem many many times and fluctuating the market cap by billions from one day to the next on a drug that should have had a generic by now. They have exceeded the 15 years patent but someone out there is protecting that patent for them. Lots of money involved here. Steal from the american public and a have a few people live well like executives and hedge funds. They bought every compund they have they don't have sophisticated science or scientists working on anything groundbreaking. Their strategy is buy an orphan compound and then get fast tracj and overbill the insurances who are in it together witht them to charge us high premiums. it's all a very intricate system. I ama pharmacist and I know exactly how these criminals work. And I refuse to let them do this . The fbi and cia and all these agencies can follow you from space and see if you have a blueberry or a blackberry in your palm they can sure as heck see all these crooked things this company is doing. They bought jzp-110 for 125 million and knew full well that this drug would have positive phase 3 results since phase 2 was good. A drug in my opinion that has no sophisticated science and is merely very similar to modafanil or any other cns stimulant out there. Same side effects like dec appetite nausea etc. So the fact that they boought vyxeos follows in the same type of trickery with all their other acquisitions. 40 year old chemo drugs combined and change the strength add a little nano encapsulation bull and presto a new drug.
  • Jazz will try its best to get out of the corner they are in with a ridiculously high 12 billion dollar market cap based on xyrem a drug that has competition coming from avadel in their once nightly dosing instead of twice nightly from jazz and the rest of their products are also dead in the water. Difitelio,erwinaze,prialt,fazaclo,versacloz are all garbage. Vyxeos is another scam taking 2 fifty y/o chemo drugs and making it a nano particle and also changing the ratio. You see you have to change things around a little bit so you can try and show that it's different from what is on the market just like vivus did when it combines two fifty year old drugs and came up with the scam known as qsymia. This is the scam companies who have no new technology nothing new nothing innovative they pull tricks like combining two old drugs changing the strengths conducting a few clinical trials knowing full well the side effects and the results. They are obviously going to be very similar to what they are trying to pretend is better than what's already being used. Jazz knows and whoever is backing them knows that they must try and find something to buy so that they can show that they have something when compared to the garbage they have now or they will try and have someone buy them. But if that happens that will be investigated for fraud and cover up. Because I have dissected what they have and compared it to what they can make from their products. If the insurances didnt allow this fraudulent overbilling by jazz they would have a market cap of 400 million. But the crooked insurance companies along with theese criminal hedge funds have allowed Jazz to rip off the american public and use those funds to purchase other assets. on the backs of hard working bancrupt Americans. The gov't and the fda and the insurances and wall st are the axis of evil. They rob Americans by creating this closed circle and they keep us enslaved. I welcome bruce cozaad or anyone to debate what I am saying.
  • Do you think craig sager the nba legend who died from Aml would have passed away and have been hospitalized for so long if there was anything effective to treat Aml? Feel free to answer me anyone
  • The upside potential for JAZZ just got a whole lot more interesting thanks to an enticing analyst mean target price of 179.65. check out awesomestoc-ks, its a pretty reliable service. of course you have to do your own due diligence, but they generally point you in the right direction.
  • We are in an economic depression and have been for 9 years. We never came out of it but they pushed the stock market up and all these stocks to enrich the executives and hedge funds while the rest of us suffer. No jobs or low paying jobs with sky high rents, housing costs, property taxes,health insurance, college tuition, life insurance etc. I as a Pharmacist have not gotten a raise for 15 years and neither have alot of other people. The only people I see making big money are these crooked hedge fund guys. Even after the 2008 financial crisis these animals are making big money. Anyway, going back to Jazz this is the only stock that I know of that is still almost at its all time high when they did what valeant and endo and teva and mylan and mallincrodt,and perrigo have done and far worse in my opinion. If we are broke and cannot afford health insurance anymore how can jazz be allowed to charge billions for xyrem a drug which is over 15 years old a drug that was otc a drug that is 50 years old. Don't you think their is fraud here? How can these people say jazz is cheap and all these lies.
  • So Moodys is banking on Jazz being able to continue getting away with charging a ridiculous price on Xyrem over 100 thousand dollars per patient on a drug that lost it's patent on a drug that will have major competition from flamel corp or now known as avadel. We are in an economic depression .Americans are broke we have been destroyed by sky high drug and hospital costs etc. The president has said drug companies" are getting away with murder"he also said that "somebody's getting very rich" he promises drug price legislation. If he is going to fix healthcare he is without a doubt going to bring down drug prices drastically. All the stocks that have been con artists and have been ripping off the public like periggo, valeant, endo pharma, horizon biopharma, mallinckrodt, teva,mylan and so many more have seen their stock prices crash. The only stock that is sky high with a ridiculous market cap of almost 12 billion dollars still is jazz pharma. Vyxeos is another scam. It's a combo drug of 2 50 year old chemo drugs dont let these guys fool you. And jzp-110 that put on 700 million in market cap just bc of 1 indication so far out of two with expected pos phase 3 results is just a me too stimulant like modafanil. So moodys has no clue what they are talking about just like they had no clue what they were doing before the financial crisis. No one with half a brain trusts them. There is competion on aml from agios pharma and bellicum to name just a few. Anyway bottom line is nthis stock is fraudulently being held up. No way in the universe this is worth 12 billion. Tops 2.5 billion and that is taking into consideration 2 billion in debt.
  • Anyone know why aeri is down 2 points after hours
  • Sorry, but Nick is a Real American person. A Pharmacist with a biology degree as well. I will be glad to debate you or any crooked analyst following this stock. these analysts tout these drugs no matter what because they don't want to lose their great job. There was an analyst two years ago recommending vivus at 32 dollars. He would have sold his own mother. He has a phd and all these fancy degrees and today vivus is 1 dollar. Thi company is no different than jazz. Vivus combined two 50 year old drugs topiramate and phentermine in an ext release capsule. They conducted clinical trials to make it look legit like jazz does. They changed the strength by a few mg to make it seem like they did these tests and at that particular strength in an ext release capsule it works better than taking the two pills independently. Now keep in mind topiramate is a 5 dollat copay if that and 30 pills of phentermine is about 17 dollars. As opposed to 200 dollars for qsymia cash. Insurances are obviously in bed with these crooked pharma companies and so is wall st. The insurance companies have financially destroyed Americans. We are paying at least 2 thousand dollars a month for health insurance for a family. Thats not including deductibles and copays. So figure 30 thousand a year for health insurance. Absolute destruction. Now if the government cared about it's people do you honestly believe they would let jazz charge a hundred thousand a year for a drug like xyrem. A drug that was over the counter a drug which was purchased for 145 million and jazz has bade billions from that has used the money to finance other acqusitions so that they can legitimize theyre 12 billion dollar market cap. they went and bought celator another scam and have enriched those con artists and crooked hedge funds that bought celator supposedly after they announced positive phase 3 results. Why would you buy after the stock had already gone up 600 percent if you did not know jazz was going to buy them. All i know is jazz is always tangled up in controversy. weather it was with orphan pharma or tax inversion or hiking up xyrem thousands of percent etc. There is no way this stock is worth 11 billion and before they bought celator the stock was even valued at 14 billion just on xyrem. I mean if this isnt fraud I don't know what is. Every company has lost 80 percent of its value and stayed there like vrx or endp or prgo or teva or mnk or myl and so many others .Jazz has a drug thats 16 years old and derives 70 percent of its revenue from and keep in mind there is plenty of competition coming. I would love someone to break down to me what is so great that they have that would even come close to valuing them at 11 billion dollars
  • looks like jazz have sured up the ship with respect to the patent litigations for xyrem - looks good for vyxeos approval in US this year and finding commercial partners in Japan for defetelio and vyxeos is significant - add to that positive clinical data from JZP110 - I would say this has pretty good growth prospects in the short to medium term. Interested to hear from others :)
  • Is "Nick" some guy in China who's paid by the shorts to talk trash about this stock?

    There's another guy named "Richard" on the Kite board who preaches the same garbage.
  • No ethical company American or japanese would buy Jazz. If Jazz was ever to be Aquired it would be to avoid bancruptcy or a crash in it's stock or so I would not be found correct in everything I have been saying here for 2 years. They can only escape from me calling them out on the fraud if someone fraudulntly buys them. Anyone who would buy them would spend 11 billion dollars. Everyone knows that the healthcare sector is being held up fraudulently like the stock market is being held up fake and fraudulently by Wall st aka globalist deep state anything you want to call these animals. they have held up the stock market for 9 years only by lies. The country and the people of the country are broke. Corporations and insiders have purposely destyroyed us.
  • when bruce cozadd was asked by analyst ken cacciatore who has no background in medicine and should not be a biotech/pharma analyst and who consistently upgrades jazz when he has no clue what hes talking about the following question and I quote "is pricing in orphan oncology as attractive as other orphan indications, or is there anything unique that wouldn't allow you to get pricing as you kind of look at the business development in that area?" The moron cozadd wanted to shift the quest to the cfo but still attempted to answer accordingly "i would say pricing really always should relate back to how effective is the product, how serious is the disease, and what's that product impact relative to other available treatments?And one of the things I think we've been highly focused on in the products that we have as part of our portfolio are finding products that really make a differencefor patients in a way that's differentiatedfrom other products" Now, is this guy kidding me or what? xyrem was bought for 125 million via buying orphan med.it was over the counter for 50 years prior to orphan med patenting sod oxybate. It neither saves lives nor was there big research done on this compound. And the same goes for vyxeos. This was a compound formed because the founders knew that it would eventually get approved or create enough hype that it would be sold to someone like jazz that can use the phase 3 results to hype up their stock. They buy compounds that are not high risk as far as getting approved because if they pass phase 2 then there is a 70 percent chance they will pass phase 3. Bruce cozadd knows how to game the system and also save taxes. Jazz is a cash cow on him but the middle class by way of large insurance premiums subsidize the jazz executives and hedge funds that own it.
  • The system is so rigged. These jazz execute made hundreds of millions by smoke and mirrors. They have made billions off of xyrem that they bought for 145 mil which was all borrowed money ofcourse and they increased the price of it thousands of percent and the crooked insurance companies that are in on the scam pay them whatever they ask. This is a deliberate thought and planned out scheme to bancrupt the middle class while enriching these executives and hedge funds etc.
  • jazz managment don't try and pretend your a takeover candidate either. I have mentioned this many times on the board. the only way they can cover the fraud is by having someone buy them over like valeant bought salix for 15 billion and now valeant is basically bancrupt. this is all criminal behavior. You think that you can charge 100 k per patient on xyrem and get rich off of the backs of middle class americans. enough already
  • didnt i say a few days ago all the "big" genius crooked analysts are going to come out of the woodworks praising jazz on what a great company it is and how great of a deal they made with hikma. They don;t mention avadels sod oxybate product is better than jazz with once nightly dosing as opposed two waking up 3 am for the second dose with xyrem. They don't mention that the healthcare industry has imploded and that consumers cannot afford these ridiculous premiums from insurance companies that they have to charge to subsidize the fraud of companies like jazz and horizon biopharma and valeant etc. They don't mention the fact that insurances can easily say we arent covering xyrem or you have a 100 copay with xyrem or you must try generic nuvigil or provigil before. This in my opinion is coming and all these criminals know it's coming that's why if you read carefully jazz sais that hikma might even manufacture before 2023. Jazz right now is valued at over 11 billion dollars. this is a market cap bigger than blue, agio, edit, once, blcm, and a handful of others combined. You mean to tell me jazz is seriously worth more than all these other companies combined because of xyrem and a few other uninnovative compounds like vyxeos. that right there is a tremendous scam
  • when avadel sod oxybate gets approved and there is no reason why it shouldnt and we are looking to get this approved in the next 6 months jazz will be left with no clothes. Right now the con artists pushing this stock price higher out of thin air will be seen by all as the frauds that they are. if you do your research you will see that jazz very sneakily creates good news to manipulate the stock higher and higher.They purposely came out with this news so right after the phase 3 news so that the stock would continue on this upward trajectory. this is all masterminded by these crooks. without xyrem they can no longer rip off the public with the help of third party insurance carriers and hedgefunds/wall st analysts creating this ponzi scheme. this company is no better than a valeant in fact in my opinion worse. Jazz uses the money they overcharge from xyrem to come up with funds to legitimize their market cap but they went and bought two compounds jzp-110 and vyxeos and these compunds have huge competion and do not look better than whats currently out there. In fact vyxeos in my opinion is a scam that has been done by other fraud companies out there like horizon biopharma and vivus.